Aug 16, 2023 / 06:00PM GMT
Danielle Joy Antalffy - UBS Investment Bank, Research Division - Analyst
Good morning, everyone. Thank you for joining us for the last session of the morning. I am Danielle Antalffy. I'm the medtech analyst in the U.S. here at UBS and very excited to have with us the company I've known for a very long time, Tandem Diabetes. CEO, John Sheridan; CFO, Leigh Vosseller. Thank you guys for joining us. I know you drove very far to get here.
John F. Sheridan - Tandem Diabetes Care, Inc. - President, CEO & Director
Thanks for having us.
Questions and Answers:
Danielle Joy Antalffy - UBS Investment Bank, Research Division - AnalystYou are welcome. So one of the questions I want to ask you guys after several years of a very strong stock performance. It's been a tough few quarters here. And I just wanted to maybe start with a question I actually usually end with. And that is, what do you think investor sell-side might be missing about the Tandem story that has been driving some of the stock underperformance recently.